Manila Times Business
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
- Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 - - Builds on completed Phase 1a study and ongoing development in HDV - SOUTH SAN FRANCISCO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced plans to expand the clinical development of ABI-6250, its oral entry inhibitor candidate for chronic hepatit
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
1h ago
Ghana's 'anti-LGBTQ' law triggers both praise and outrage
2h ago
WHO chief visits epicentre of Ebola outbreak in DR Congo
2h ago
Vapofil Reviews [URGENT REPORT 2026] The Shocking VapoFil Male Enhancement Supplement Trend Everyone Is Talking About
2h ago